TOKYO -- Japanese companies such as Nikon and materials maker AGC plan to invest a total of over 100 billion yen ($675 million) by fiscal 2027 to boost production of stem cell-based and other cutting-edge drugs, an area where Japan trails the U.S. and Europe.
Pharmaceuticals
Japan's Nikon, others to invest $675m in cutting-edge drug production
Companies look to tap rising demand for regenerative medicines
Nikon and other companies produce advanced therapies, some using stem cells, on a contract basis. (Photo obtained by Nikkei)
Read Next
Latest on Pharmaceuticals
